Did you know? Our Board-Certified Specialists. Inactive RTK System. Activated RTK System
|
|
- Rosalind Terry
- 7 years ago
- Views:
Transcription
1 Did you know? ASH is the only hospital in Southwest Florida to have 7 boardcertified specialists under one roof ASH is the only hospital on the Gulf coast to have both MRI and CT on site V O L U M E 1, I S S U E 2 N O V E M B E R Palladia A Novel Receptor Tyrosine Kinase Inhibitor with Antiangiogenic and Antiproliferative Properties and Its Use in Small Animal Oncology Lisa DiBernardi, DVM, Diplomate ACVIM (Oncology), Diplomate ACVR (Radiation Oncology) Referrals are accepted and specialists are oncall 24/7/365 Our Board-Certified Specialists Ashley Ayoob, DVM, DACVIM (Medicine), DACVECC Michelle Carnes, MS, DVM, DACVIM (Neurology) Lisa DiBernardi, DVM, DACVIM (Oncology), DACVR (Radiation Oncology) Brandy Dugas, DVM, DACVIM (Medicine) Marc Havig, DVM, DACVS, CCRP Introduction Palladia (toceranib phosphate) is the first FDA approved antiangiogenic and antiproliferative cancer treatment specifically for dogs. This drug is a member of a class of drugs called small molecule inhibitors and shares this class with human approved drugs such as Avastin, Torisel, Gleevec and Sutent. Palladia is an orally administered receptor tyrosine kinase (RTK) inhibitor, blocking the function of various receptors leading to its antiangiogenic and antiproliferative activity. To permit the formation of a clinically relevant tumor, the work of Dr. Folkman demonstrated the necessity for the cells to establish a vascular supply. Therefore, the principles of tumor angiogenesis are fundamental for an understanding of tumor biology. This offers the potential to offer novel avenues for tumor control. Angiogenesis and vasculogenesis are two processes resulting in the formation of vascular structures in normal and pathological conditions. Vasculogenesis versus angiogenesis: Vasculogenesis is new vessel formation from in situ bone marrow derived progenitor cells. Angiogenesis is the in growth of blood vessels sprouting off of preexisting arteries. Protein tyrosine kinases (TK) are located on the surface of cells, within the cytoplasm and nucleus. They are enzymes responsible for the activation of proteins (tyrosine residues). This action plays an integral role in the regulation of signal transduction and consequently the regulation of gene expression. Receptor tyrosine kinases (RTK) are a class of cell membrane receptors with high affinity for many growth factors, cytokines and hormones. RTK have been shown not only to be key regulators of normal cellular processes but also have a critical role in the development and progression of many types of cancer through signaling pathways involved in angiogenesis. Their role is thought to be through the stimulation of biochemical reactions such as cell survival, migration, proliferation and gene activation. (Continued on next page) Nick Schroeder, DVM, DACVIM (Cardiology) Christi Warren, DVM, DACVO Schleesinger J. Cell. 2000;103: Inactive RTK System Activated RTK System
2 P A G E 2 Palladia A Novel Receptor Tyrosine Kinase Inhibitor with Antiangiogenic and Antiproliferative Properties and Its Use in Small Animal Oncology Palladia is indicated for use in recurrent Grade II or III cutaneous mast cell tumors. (continued from last page) As seen in the figures on the previous page, cell surface RTKs are activated once bound to growth factors. Once activated, RTK downstream signaling molecules carry out cellular responses such as abnormal cell growth and signaling. Dysregulation of RTKs can result in a cellular response (activation) despite the lack of growth factor binding. This dysregulation enhances inappropriate cell signaling and may cause volatility in the regulation of cell growth and cell survival. The cell membrane receptor important for the growth, adhesion, migration and survival of mast cells is Kit (CD 117). KIT is often dysregulated in mast cell tumors of both dogs and cats and Palladia not only inhibits mutated Kit but also non mutated Kit. There are other receptor tyrosine kinases inhibited by Palladia. These are vascular endothelial growth factor receptor 2 (VEGFR-2) located on endothelial cells, and platelet derived growth factor receptor-b (PDGFR-b) found on pericytes (connective tissue cell found around small blood vessels). Studies utilizing mouse models have recognized through combined inhibition of both VEGFR-2 and PDGFR-b tumor regression takes place. to be the driving force for the initiation and progression of angiogenesis. The presence of hypoxia initiates the release of vascular endothelial growth factor (VEGF) and platelet derived growth factor. When these substances bind to their receptor tyrosine kinases (PDGFR-b and VEGFR-2, respectively) they become key building blocks for tumor angiogenesis. Bergers et al., showed evidence of tumor vascular disruption through the blockade of PDGFR-b. With the addition of blockade of both PDGFR-b and VEGFR, Potapova et al., witnessed enhanced regression of tumor vasculature in addition to blocking either receptor alone. Mast Cell Tumors When the KIT RTK binds to its growth factor, stem cell factor (SCF), this incites a series of downstream events essential for mast cells to develop and grow. In cultured cells, blockade of these events caused the cells to undergo apoptosis. Inhibition of KIT occurs in a clinically achievable Palladia serum concentration. Palladia is indicated for use in recurrent Patnaik Grade II or Grade III cutaneous mast cell tumors having or lacking regional lymph node involvement. Therefore the standard of care in localized mast cell tumors is still surgical excision. Incompletely resected grade II tumors with microscopic disease have a 2 year control rate of 85-95% after treatment with external beam radiation. In areas where radiation is not available a second surgery or chemotherapy may be viable treatment alternatives. First line of therapy in regional or distant mast cell disease is chemotherapy and in some cases adjunctive radiation therapy. Frequently utilized first line treatments are often a combination or as single agent chemotherapeutics such as vinblastine, CCNU ( l o m u s t i n e ), L e u k e r a n (chlorambucil), cyclophosphamide, vinorelbine and prednisone. (Continued on next page.) Regulation of Angiogenesis Hypoxia is believed
3 V O L U M E 1, I S S U E 2 P A G E 3 (Continued from opposite page) Response rates achieving either partial or complete responses for single agent treatment of mast cell tumor ranges between 7-42% with potentially improved results with combination chemotherapy (46-64% response rate). Palladia therapy is typically instituted once a patient fails the standard mast cell tumor treatments, or if the patient presents with a non surgical localized mast cell tumor (with or without regional metast a s i s ). The cost of a 30 day supply of Palladia for a 60 lb dog ranges from $600-$1,000 depending on the distributor plus the cost of diagnostics etc. 22 dogs with Mast cell tumor were evaluated by London et al.; 50% of dogs had either a complete or partial response with 59% of dogs having a biological response (stable disease for 10 weeks or a partial or complete response). Palladia Dosing, Response and Side Effects In Phase I Clinical Trials the maximum tolerated dose of Palladia was determined to be 3.25mg/kg orally EOD. However, doses as low as 2.7mg/kg dosed on a Monday-Wednesday-Friday schedule have been shown to be effective. Tablet strengths are 10mg, 15mg and 50mg. These tablets are coated and should not be divided. Palladia is primarily metabolized by the liver and concurrent use of drugs known to inhibit cytochrome P450 enzyme CYP3A4 (cimetidine, omeprazole) may elevate serum concentrations and predispose the patient to side effects. Most Palladia induced side effects are mild to moderate however some can be serious. The most commonly experienced side effects are: diarrhea (46%), anorexia (39%), lethargy (35%), emesis (32%), neutropenia (46%), and lameness (17%). Instituting a 2 week rest from Palladia administration is warranted if severe diarrhea, gastrointestinal ulceration, neutropenia (<1000), anemia, azotemia, hypoalbuminemia, or hyperphosphatemia occur. Concurrent use of NSAID s increases the risk of gastrointestinal ulceration. Therefore other methods of pain or arthritis control such as opioids should be considered. Dogs with advanced diseased states or concurrent illnesses have a g r e a t e r l i k e l i - hood of undesirable side effects. A patient with systemic mast cell disease is predisposed to mast cell degranulation and potential life threatening side effects if treated with Palladia. Often prevention of gastrointestinal side effects with antihistamine, antacids and antiemetic agents is instituted prior to or at the start of Palladia. Dose reductions or schedule change are implemented after an adverse event(s). Patients should have a complete blood count, biochemistry profile, urinalysis, urine protein creatinine ratio and blood pressure prior to initiating Palladia and every 4-6 weeks there after. Response rates of 50% have been reported - Biological response is a newer and more appropriate evaluator of response with targeted therapies. The goal in veterinary oncology is to permit a good quality of life. While there is no standardized measurement for quality of life, the majority of owners report good quality of life with Palladia administration. Palladia Use in Cats and in Dogs With Non Mast Cell Tumor Cancer (Compassionate Use) Currently there is an ongoing clinical trial evaluating the use Palladia in feline oral squamous cell carcinoma; anecdotal administration in cats has yielded minimal results in the area of oral squamous cell carcinoma and injection site sarcomas. However to date we are lacking controlled prospective evaluation of Palladia for the use in feline mast cell disease. In the dog, reports of responses have been identified with metastatic tumors. These have included: gastrointestinal stromal cell tumors, osteosarcoma, thyroid carcinoma and anal sac apocrine gland adenocarcinomas, to name a few. The majority of these patients had long term stable disease. The majority of patients under Palladia treatment for non mast cell tumor disease fortunately subjectively have a lower side effect rate than the mast cell tumor patients. Summary The standard of care for localized low to intermediate grade mast cell tumors is surgery. There is a clear need to supplement the standard mast cell tumor treatments in patients that are poor surgical candidates or have limited surgical options. Palladia offers a good opportunity for disease control. Side effects should be anticipated and addressed early and aggressively.
4 ASH Events Calendar Enjoy time off during the Holidays ASH is open 24/7/365 to handle all of your Holiday Emergencies!! Sun Mon Tue Wed Thu Fri Sat 1 Happy New Year! January Botanical Garden Dog Day* 22 Pets On Third* Run for the Paws 5K* *Events sponsored by ASH Contact ASH for more information. Spotlight on: Dr. Lisa DiBernardi Lisa DiBernardi, DVM, DACVIM (Oncology), DACVR (Radiation Oncology) Dr. Lisa DiBernardi is now seeing appointments on both Mondays and Wednesdays. Since completion of her medical oncology and radiation oncology boardcertifications, Dr. DiBernardi has been in private practice in Texas and Florida for the past 7 years. In addition to seeing patients, Dr. DiBernardi volunteers her veterinary services at special event venues, such as Dolphin Stadium where she worked with the canine detection teams. In addition, she has treated several cancer patients of the Miami Metro Zoo and Lion Country Safari. Dr. DiBernardi s professional interests include clinical pathology and pain management. She has presented research nationally and is a member of the Veterinary Cancer Society. She participates in clinical trials with the Veterinary Radiation Therapy and Oncology Group and Animal Clinical Investigators group. Dr. DiBernardi routinely performs biopsy, fine needle aspiration and cytology, bone marrow aspirates and pathology report consultation. Treatments that may be incorporated for cancer therapy include: chemotherapy, clinical trials, immunotherapy and radiation therapy. Dr. DiBernardi is one of < 15 doubleboarded medical and radiation oncologists in the World
5 Quick Case of the Month: The Melanoma Vaccine Bailey, a 10 year old male neutered Shih Tzu mix, presented to the oncology department at ASH for evaluation of a previously excised oral melanoma with microscopic disease at the surgical site. Bailey s original mass was located on the gingiva near the right upper premolar. The mass was described as a pigmented, pedunculated soft tissue mass 2cm in size. Prior to a second surgery to remove microscopic disease, fine needle aspirate of the mandibular lymph nodes (ipsilateral and contralateral nodes due to variability in draining patterns) were submitted for review, as well as three view thoracic radiographs and abdominal ultrasound. A complete blood count and biochemistry profile and urinalysis were performed at the initial surgery. All diagnostic tests were negative for any metastasis and a second surgery was scheduled to remove the remaining microscopic disease. A right segmental maxillectomy extending from the 1st molar to the first pre-molar tooth was performed to assure complete surgical excision. Oncept canine melanoma vaccine was initiated. The vaccine (0.4ml) was administered transdermally to the medial thigh every two weeks. A total of four initial treatments are administered then one vaccine every six months thereafter. Bailey is doing well (6 months post-op); he has had no side effects from the vaccine or the administration of the vaccine and has no local or metastatic evidence of melanoma. His prognosis prior to Oncept with treatment was approximately only a 1 year survival. However, he is expected to have a greater then two year survival after vaccine administration. Canine oral melanoma is the most common malignant oral tumor of the dog. It also occurs in the nail and footpad. These tumors are aggressive and frequently metastasize to the lymph nodes, lungs, and abdominal organs. Local control may be achieved through surgery, radiation therapy or a combination of the two. However, most dogs will succumb to metastatic disease therefore a systemic treatment to delay or prevent metastasis is necessary. The Oncept vaccine was developed through a partnership between Merial and Memorial Sloan-Kettering Cancer Center and has been available to veterinary oncologists since March The vaccine is delivered via a needless system and local reactions are limited to acute wheal, hematoma formation, discomfort and or bruising at the site of administration. The American Journal of Veterinary Research December 2011 revealed the median survival time could not be determined for vaccinates because < 50% died of melanoma before the end of the observation period. No systemic reactions requiring veterinary intervention have been associated with vaccination. The cost of the initial vaccine series is approximately $2500; while this may seem expensive, we are now able to provide patients with malignant melanoma a great quality and quantity of life. If you have a patient that may be a candidate for the melanoma vaccine, please contact Dr. DiBernardi at Market St. Suite 1 Naples, FL (phone) (fax) info@ashfl.com
LYMPHOMA IN DOGS. Diagnosis/Initial evaluation. Treatment and Prognosis
LYMPHOMA IN DOGS Lymphoma is a relatively common cancer in dogs. It is a cancer of lymphocytes (a type of white blood cell) and lymphoid tissues. Lymphoid tissue is normally present in many places in the
More informationOsteosarcoma: treatment beyond surgery
Osteosarcoma: treatment beyond surgery Eric Chow, DVM DACVS Sue Downing, DVM DACVIM-Oncology Providing the best quality care and service for the patient, the client, and the referring veterinarian. Osteosarcoma
More information1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT
1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT Learning that your pet has a diagnosis of cancer can be overwhelming. We realize that your pet
More informationP! P! P! 2nd Mess! P! P! P! P! P! Signaling Cascade. Signaling Cascade. Signaling Cascade. Signaling Cascade. Signaling Cascade
Vaccine-Associated! Sarcoma! Hemangiosarcoma! Mast Cell Tumor! Osteosarcoma! 10 11! Survival! Survival Migration/Invasion! Survival Migration/Invasion Angiogenesis! Survival Migration/Invasion Angiogenesis
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationCanine Lymphoma Frequently Asked Questions by Pet Owners
Canine Lymphoma Frequently Asked Questions by Pet Owners What is lymphoma? The term lymphoma describes a diverse group of cancers in dogs that are derived from white blood cells called lymphocytes. Lymphocytes
More informationVeterinary Oncology: The Lumps We Hate To Treat
Veterinary Oncology: The Lumps We Hate To Treat Michelle Turek, DVM, DACVIM (Oncology), DACVR (Radiation Oncology) College of Veterinary Medicine University of Georgia Athens, GA Veterinary Oncology Veterinary
More informationSmoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer.
Renal cell cancer Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. Renal cell cancer (also called kidney cancer or renal adenocarcinoma) is a disease in which
More informationStaging for Common Cancers in Dogs & Cats. Medical Insurance For Your Pet. Partially Sponsored By:
Partially Sponsored By: Medical Insurance For Your Pet Call 877.589.1863 or visit them at www.trupanion.com 129 Glover Ave Norwalk, CT 06850 P (203) 838-6626 F (203) 838-6640 Website: www.vcchope.com Email:
More informationMetastatic Breast Cancer...
DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationAnaplastic Thyroid Cancer:
1 Anaplastic Thyroid Cancer: A Doctor s Perspective for Patients and Families Living with the Disease By Maria E. Cabanillas, M.D., F.A.C.E. Associate Professor and Faculty Director of Clinical Research
More informationTargeted Therapies in Lung Cancer
Targeted Therapies in Lung Cancer I Edited by: Simona Carnio Thoracic Oncology Division - St Luigi Hospital Orbassano (TO) - Italy Silvia Novello Department of Oncology - University of Torino - Italy Why
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationLess stress for you and your pet
Less stress for you and your pet Canine hyperadrenocorticism Category: Canine Cushing s disease, Cushing s syndrome Affected Animals: Although dogs of almost every age have been reported to have Cushing
More information.org. Metastatic Bone Disease. Description
Metastatic Bone Disease Page ( 1 ) Cancer that begins in an organ, such as the lungs, breast, or prostate, and then spreads to bone is called metastatic bone disease (MBD). More than 1.2 million new cancer
More informationOncology Quarterly. Corky and Kaylee Smith
Oncology Quarterly Volume 2 Winter 2007 Corky and Kaylee Smith For Richard and Monica Smith, it started simply as a small area of hair loss on their eight yearold Shetland Sheepdog, Corky s, left tarsus.
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationThe various anatomical forms of feline lymphoma (mediastinal, alimentary, renal, multicentric and extranodal) have been well described.
Decision Making in Feline Cancer Patients David J. Argyle, BVMS, PhD, DECVIM-CA (Oncology), MRCVS Royal (Dick) School of Veterinary Studies Hospital for Small Animals Easter Bush, Midlothian, UK Introduction
More informationtargeted therapy a guide for the patient
targeted therapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2-3 Gene changes... 4-5 Testing... 7-8 Targeted therapy... 9-11 Drugs Targeting EGFR... 12 Drugs Targeting
More informationMetastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies
More informationThe following information is only meant for people who have been diagnosed with advanced non-small cell
Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC
More informationUnderstanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient
Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that
More informationOncology. Objectives. Cancer Nomenclature. Cancer is a disease of the cell Cancer develops when certain cells begin to grow out of control
Oncology Objectives Describe the etiology and pathophysiological mechanisms of cancer Discuss medical and family history findings relevant to cancer Identify general signs and symptoms associated with
More informationLung cancer is not just one disease. There are two main types of lung cancer:
1. What is lung cancer? 2. How common is lung cancer? 3. What are the risk factors for lung cancer? 4. What are the signs and symptoms of lung cancer? 5. How is lung cancer diagnosed? 6. What are the available
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationUs TOO University Presents: Understanding Diagnostic Testing
Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by
More informationDiagnosis and Prognosis of Pancreatic Cancer
Main Page Risk Factors Reducing Your Risk Screening Symptoms Diagnosis Treatment Overview Chemotherapy Radiation Therapy Surgical Procedures Lifestyle Changes Managing Side Effects Talking to Your Doctor
More informationComprehensive Cancer Center
Comprehensive Cancer Center at Veterinary Specialists of South Florida Our goal is to provide your companion with gentle, compassionate, advanced diagnostics and treatment while focusing on quality of
More informationInnovations in Kidney Cancer
Innovations in Kidney Cancer Guest Expert: Harriet, MD Associate Professor of Medical Oncology Edward, MD Assistant Professor of Surgical Urology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer
More informationThymus Cancer. This reference summary will help you better understand what thymus cancer is and what treatment options are available.
Thymus Cancer Introduction Thymus cancer is a rare cancer. It starts in the small organ that lies in the upper chest under the breastbone. The thymus makes white blood cells that protect the body against
More informationThe Comprehensive Cancer Care Team at Penn Vet s Ryan Hospital CORE TEAM
The Comprehensive Cancer Care Team at Penn Vet s Ryan Hospital Ryan Hospital s Comprehensive Cancer Care Program is led by a world- class team of board- certified veterinarians who each offer a unique
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress Rescue Chemotherapy Protocols for Dogs with Lymphoma Kenneth M. Rassnick, DVM, DACVIM (Oncology) Cornell University
More informationThese rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.
Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of
More informationWhat is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
More informationOBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
More informationHow To Treat Lung Cancer At Cleveland Clinic
Treatment Guide Lung Cancer Management The Chest Cancer Center at Cleveland Clinic, which includes specialists from the Respiratory Institute, Taussig Cancer Institute and Miller Family Heart & Vascular
More informationUnderstanding. Pancreatic Cancer
Understanding Pancreatic Cancer Understanding Pancreatic Cancer The Pancreas The pancreas is an organ that is about 6 inches long. It s located deep in your belly between your stomach and backbone. Your
More informationYour Guide to Express Critical Illness Insurance Definitions
Your Guide to Express Critical Illness Insurance Definitions Your Guide to EXPRESS Critical Illness Insurance Definitions This guide to critical illness definitions will help you understand the illnesses
More informationDrug treatments for kidney cancer
James Whale Fund for Kidney Cancer Drug treatments for kidney cancer Before your doctors can discuss treatment options with you they need to know how far your cancer has progressed. Staging is used to
More informationNew strategies in anticancer therapy
癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive
More informationIntroduction Breast cancer is cancer that starts in the cells of the breast. Breast cancer happens mainly in women. But men can get it too.
Male Breast Cancer Introduction Breast cancer is cancer that starts in the cells of the breast. Breast cancer happens mainly in women. But men can get it too. Many people do not know that men can get breast
More informationMetastatic Melanoma What You Need to Know
ESSENTIALS Metastatic Melanoma Metastatic Melanoma What You Need to Know If you have metastatic melanoma, you may feel as though your life has been turned upside down. It s a serious disease, but patients
More informationPreliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors
Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors John Goldberg 1 *, George Demetri 2, Edwin Choy 3, Lee Rosen 4, Alberto
More informationExelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationI've Just Been Diagnosed. with Kidney Cancer: What s Next?
I've Just Been Diagnosed with Cancer: What s Next? Table of Contents Introduction Message from a Survivor What are the s and What is Their Function? What is Cancer? What are the Types of Cancer? What are
More informationFrequently Asked Questions About Ovarian Cancer
Media Contact: Gerri Gomez Howard Cell: 303-748-3933 gerri@gomezhowardgroup.com Frequently Asked Questions About Ovarian Cancer What is ovarian cancer? Ovarian cancer is a cancer that forms in tissues
More informationThe Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in Breast Cancer
BIT's 4th World Cancer Congress 2011 People s Republic of China Dalian The Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in treated with DBM therapy Retrospective observational
More informationWhat is Glioblastoma? How is GBM classified according to the WHO Grading System? What risk factors pertain to GBM?
GBM (English) What is Glioblastoma? Glioblastoma or glioblastoma multiforme is one of the most common brain tumors accounting for approximately 12 to 15 percent of all brain tumors. The name of the tumor
More informationBreast Cancer. CSC Cancer Experience Registry Member, breast cancer
ESSENTIALS Breast Cancer Take things one step at a time. Try not to be overwhelmed by the tidal wave of technical information coming your way. Finally you know your body best; you have to be your own advocate.
More informationA912: Kidney, Renal cell carcinoma
A912: Kidney, Renal cell carcinoma General facts of kidney cancer Renal cell carcinoma, a form of kidney cancer that involves cancerous changes in the cells of the renal tubule, is the most common type
More informationGeneral Information About Non-Small Cell Lung Cancer
General Information About Non-Small Cell Lung Cancer Non-small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. The lungs are a pair of cone-shaped breathing
More informationGenetics Gender plays a role in kidney cancer, as men are twice as likely as women to develop RCC
What is kidney cancer? Renal cell carcinoma (RCC) is the most common kind of kidney cancer. 1 Normally, your kidneys filter your blood and excrete waste in urine. Although our kidneys are important, we
More informationTargeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
More informationBrigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA
Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS 6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Resectable Malignant Pleural Mesothelioma
More informationCancercare Connect Booklet Series. Renal Cell Cancer. www.cancercare.org
Cancercare Connect Booklet Series Treatment Update Renal Cell Cancer www.cancercare.org Treatment Update Renal Cell Cancer Table of Contents The CancerCare Connect Booklet Series offers up-to-date, easy-to-read
More informationSurgery. Wedge resection only part of the lung, not. not a lobe, is removed. Cancer Council NSW
The treatment you receive will depend on your lung cancer type, for example, whether you have a non-small cell lung cancer Adenocarcinoma or Squamous cell carcinoma, and if this is a sub-type with a mutation.
More informationWhat You Need to Know About Lung Cancer Immunotherapy
What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer
More informationNew Treatment Advances for Breast Cancer
New Treatment Advances for Breast Cancer Guest Expert: Lyndsay, MD Director of the Yale Cancer Center Breast Cancer Program Gina ng, MD www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center
More informationThe Biological Basis of Cancer. Annie Young, Professor of Nursing, University of Warwick, University Hospitals Coventry and Warwickshire
The Biological Basis of Cancer Annie Young, Professor of Nursing, University of Warwick, University Hospitals Coventry and Warwickshire Aim of Presentation By the end of this presentation you will: Be
More informationThe TV Series. www.healthybodyhealthymind.com INFORMATION TELEVISION NETWORK
The TV Series www.healthybodyhealthymind.com Produced By: INFORMATION TELEVISION NETWORK ONE PARK PLACE 621 NW 53RD ST BOCA RATON, FL 33428 1-800-INFO-ITV www.itvisus.com 2005 Information Television Network.
More informationPATIENT INFORMATION ABOUT ADJUVANT THERAPY AFTER THE WHIPPLE OPERATION FOR ADENOCARCINOMA ( CANCER ) OF THE PANCREAS AND RELATED SITES.
PATIENT INFORMATION ABOUT ADJUVANT THERAPY AFTER THE WHIPPLE OPERATION FOR ADENOCARCINOMA ( CANCER ) OF THE PANCREAS AND RELATED SITES. Radiation Oncology Sidney Kimmel Cancer Center at Johns Hopkins Last
More informationLung Cancer Treatment Guidelines
Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,
More informationStage I, II Non Small Cell Lung Cancer
Stage I, II Non Small Cell Lung Cancer Best Results T1 (less 3 cm) N0 80% 5 year survival No Role Adjuvant Chemotherapy Radiation Therapy Reduces Local Recurrence No Improvement in Survival 1 Staging Mediastinal
More informationPost-PET Restaging Cancer Form National Oncologic PET Registry
Post-PET Restaging Cancer Form National Oncologic PET Registry Facility ID #: Registry Case Number: Patient Name: Your patient had a PET scan on: mm/dd/yyyy. The PET scan was done for restaging of (cancer
More informationMesothelioma. 1995-2013, The Patient Education Institute, Inc. www.x-plain.com ocft0101 Last reviewed: 03/21/2013 1
Mesothelioma Introduction Mesothelioma is a type of cancer. It starts in the tissue that lines your lungs, stomach, heart, and other organs. This tissue is called mesothelium. Most people who get this
More informationColorectal Cancer Treatment
Scan for mobile link. Colorectal Cancer Treatment Colorectal cancer overview Colorectal cancer, also called large bowel cancer, is the term used to describe malignant tumors found in the colon and rectum.
More informationRESEARCH EDUCATE ADVOCATE. Just Diagnosed with Melanoma Now What?
RESEARCH EDUCATE ADVOCATE Just Diagnosed with Melanoma Now What? INTRODUCTION If you are reading this, you have undergone a biopsy (either of a skin lesion or a lymph node) or have had other tests in which
More informationCMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014
Background CMScript Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014 Prostate cancer is second only to lung cancer as the leading cause of cancer-related deaths in men. It is
More informationSmall cell lung cancer
Small cell lung cancer Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. The lungs are a pair of cone-shaped breathing organs that are found within
More informationDisease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? www.simpsonmillar.co.uk Telephone 0844 858 3200
GUIDE TO ASBESTOS LUNG CANCER What Is Asbestos Lung Cancer? Like tobacco smoking, exposure to asbestos can result in the development of lung cancer. Similarly, the risk of developing asbestos induced lung
More informationTHYROID CANCER. I. Introduction
THYROID CANCER I. Introduction There are over 11,000 new cases of thyroid cancer each year in the US. Females are more likely to have thyroid cancer than men by a ratio of 3:1, and it is more common in
More informationYour Certified Professional Cancer Coach. An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer
Your Certified Professional Cancer Coach An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer The CPCC Patient Program Nutrition & Lifestyle Oncology A Cancer Diagnosis
More informationManaging Lymphoma. Professor Clare Knottenbelt BVSc MSc DSAM MRCVS
Managing Lymphoma Professor Clare Knottenbelt BVSc MSc DSAM MRCVS Lymphoma Common cancer (18% of dog cancers) DOGS: Multicentric CATS: Alimentary Presentation varies with site of LSA and paraneoplastic
More informationBreast Cancer. Sometimes cells keep dividing and growing without normal controls, causing an abnormal growth called a tumor.
Breast Cancer Introduction Cancer of the breast is the most common form of cancer that affects women but is no longer the leading cause of cancer deaths. About 1 out of 8 women are diagnosed with breast
More informationUnderstanding Metastatic Disease
Supported by an unrestricted educational grant from Pfizer Understanding Metastatic Disease Metastatic disease or metastases are phrases that mean the same as Secondary cancer. This means that the cancer
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationCancer: DNA Synthesis, Mitosis, and Meiosis
Chapter 5 Cancer: DNA Synthesis, Mitosis, and Meiosis Copyright 2007 Pearson Copyright Prentice Hall, 2007 Inc. Pearson Prentice Hall, Inc. 1 What Is Cancer? Benign tumors do not invade surrounding tissue
More informationAvastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
More informationDetection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
More informationAggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
More informationLung Cancer: Diagnosis, Staging and Treatment
PATIENT EDUCATION patienteducation.osumc.edu Lung Cancer: Diagnosis, Staging and Treatment Cancer begins in our cells. Cells are the building blocks of our tissues. Tissues make up the organs of the body.
More informationACUTE MYELOID LEUKEMIA (AML),
1 ACUTE MYELOID LEUKEMIA (AML), ALSO KNOWN AS ACUTE MYELOGENOUS LEUKEMIA WHAT IS CANCER? The body is made up of hundreds of millions of living cells. Normal body cells grow, divide, and die in an orderly
More informationDepartment of BioScience Technology Chung Yuan Christian University 2015/08/13
Department of BioScience Technology Chung Yuan Christian University 2015/08/13 Cancer Cells Cancer, the 1st leading cause of death, is an example of a disease that arises from abnormalities in cell function
More informationImmune-Mediated Low Platelet or Thrombocyte Count
rally is Customer Name, Street Address, City, State, Zip code Phone number, Alt. phone number, Fax number, e-mail address, web site Immune-Mediated Low Platelet or Thrombocyte Count (Thrombocytopenia)
More informationAdjuvant Therapy for Breast Cancer: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Adjuvant Therapy for Breast
More informationProtein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
More informationLung Cancer Research: From Prevention to Cure!
Lung Cancer Research: From Prevention to Cure! Ravi Salgia, M.D, Ph.D Associate Professor of Medicine Director, Thoracic Oncology Research Program Department of Medicine Section of Hematology/Oncology
More informationCancer is the leading cause of death for Canadians aged 35 to 64 and is also the leading cause of critical illness claims in Canada.
Underwriting cancer In this issue of the Decision, we provide an overview of Canadian cancer statistics and the information we use to make an underwriting decision. The next few issues will deal with specific
More informationClinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed in the management of: LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA Patient information given at each stage following agreed information
More informationLymphoma Diagnostics, Standard of Care Treatment Options and Rescue Options
Lymphoma Diagnostics, Standard of Care Treatment Options and Rescue Options Kelvin Kow, DVM, DACVIM (Medical Oncology) University of Florida College of Veterinary Medicine Lymphoma is the most common malignancy
More informationBreast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D.
Breast Cancer: from bedside and grossing room to diagnoses and beyond Adriana Corben, M.D. About breast anatomy Breasts are special organs that develop in women during puberty when female hormones are
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationThis 2-part article will discuss 9 anticancer. Commonly Used Chemotherapy Drugs Part 1. M e d i c a t i o n s. Clinician s Brief.
M e d i c a t i o n s O N C O L O G Y Peer Reviewed Antony Moore, BVSc, MVSc, Diplomate ACVIM (Oncology) Veterinary Oncology Consultants, Sydney, Australia Commonly Used Chemotherapy Drugs Part 1 This
More informationThe Anorexic Cat For this reason, any cat that stops eating for any reason is considered an emergency situation.
The Anorexic Cat Introduction Any cat that stops eating (anorexic) or begins to eat much less than their normal amount should be seen by a veterinarian right away. The primary reason why a cat stops eating
More informationa Phase 2 prostate cancer clinical trial is ongoing. Table 2: Squalamine vs Standard-of-care literature
PRODUCT FACT SHEET Spring 2007 MISSION STATEMENT Genaera Corporation is a biopharmaceutical company with a focus on metabolic and respiratory diseases. The compounds in the Genaera pipeline address signal
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationOmega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9
Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer
More information